SB
CMPX icon

SIG Brokerage’s Compass Therapeutics CMPX Stock Holding History

SIG Brokerage’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-40,000
Closed -$76K – 724
2025
Q1 		$76K Buy
+40,000
New +$106K ﹤0.01% 514

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SIG Brokerage's CMPX Position: Q1 2026 in Review

SIG Brokerage reduced its Compass Therapeutics (CMPX) stake by 15% in Q1 2026, selling an estimated $14.9K and leaving 14,496 shares worth $76.7K. The position accounts for ﹤0.01% of the portfolio, ranked #743.

SIG Brokerage first reported a position in CMPX in Q2 2025 and has held it in 4 quarters since. The position peaked at $94.6K in Q2 2025. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • SIG Brokerage held 14,496 shares of Compass Therapeutics worth $76.7K as of Q1 2026.
  • SIG Brokerage sold 2,580 Compass Therapeutics shares in Q1 2026, an estimated $14.9K.
  • Compass Therapeutics made up ﹤0.01% of SIG Brokerage's portfolio in Q1 2026, its #743 holding.
  • SIG Brokerage first reported a position in Compass Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • SIG Brokerage's Compass Therapeutics position peaked at $94.6K in Q2 2025.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on SIG Brokerage's 13F filing for Q1 2026, filed 15 May 2026.